Experts provided information on the current status of combination immunotherapy, adjuvant immune checkpoint blockade and long-term survival after PD-1 inhibitor therapy in the course of two satellite symposia at the German Skin Cancer Congress.
Experts provided information on the current status of combination immunotherapy, adjuvant immune checkpoint blockade and long-term survival after PD-1 inhibitor therapy in the course of two satellite symposia at the German Skin Cancer Congress.
Input your search keywords and press Enter.